Lin Shang, Wei Ya-Ru, Yao Hong-Xiang
Department of Nuclear Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325002, People's Republic of China.
Department of Radiology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325002, People's Republic of China.
Int J Gen Med. 2021 Dec 14;14:9707-9718. doi: 10.2147/IJGM.S339946. eCollection 2021.
Hundreds of studies have reported the application of iodine-131 (I-131) in thyroid carcinoma (THCA) in past years. However, the status of research in the field and other related topics have not been investigated. This study aimed to identify the cooperation of authors, countries, and institutions, as well as explore the hot topics and prospects regarding I-131 therapy in THCA based on previous studies.
Publications from 2010 to 2020 were retrieved from Web of Science Core Collection according to research strategy. Bibliometric analyses were performed using VOSviewer 1.6.15 and CiteSpace 5.7.3 to evaluate and visualize the cooperation network, hot topic, and research frontier.
The number of publications showed a trend of fluctuation between 2010 and 2020. We identified 1387 publications related to I-131 therapy in THCA, which were published by 1628 institutions from 82 countries. The largest proportion of publications were emanated from the USA, and the majority of papers were published by Thyroid. Shanghai Jiao Tong University of China contributed the most papers. Although many authors participated in the research of this field, high-yield authors were few. Co-occurrence analysis classified keywords into five clusters, including assessment, efficacy measurement, monitoring, hormone regulation, and guidelines of I-131 therapy. The terms "bone marrow dosimetry and time" were among the latest hotspots. The research frontier topic in I-131 therapy focused on the "P53 and anti-Müllerian hormone".
The attention to I-131 therapy in THCA should be increased considerably. It was necessary to construct active co-operations between authors, countries, and institutions to promote the development of this field. Recent researches referred to the timing and dose assessment of I-131 therapy in THCA. Future studies likely focused on targeted therapy and adverse effects evaluation were worthy of research as well.
过去数年里，数百项研究报道了碘-131（I-131）在甲状腺癌（THCA）中的应用。然而，该领域的研究现状及其他相关主题尚未得到调查。本研究旨在识别作者、国家和机构之间的合作情况，并基于既往研究探索I-131治疗THCA的热点话题及前景。
根据研究策略，从Web of Science核心合集中检索2010年至2020年的出版物。使用VOSviewer 1.6.15和CiteSpace 5.7.3进行文献计量分析，以评估和可视化合作网络、热点话题及研究前沿。
2010年至2020年间，出版物数量呈波动趋势。我们识别出1387篇与I-131治疗THCA相关的出版物，这些出版物由来自82个国家的1628个机构发表。出版物数量占比最大的来自美国，大多数论文发表于《甲状腺》杂志。中国上海交通大学发表的论文数量最多。尽管该领域有众多作者参与研究，但高产作者较少。共现分析将关键词分为五个聚类，包括I-131治疗的评估、疗效测量、监测、激素调节及指南。“骨髓剂量测定与时间”是最新热点之一。I-131治疗的研究前沿主题聚焦于“P53和抗苗勒管激素”。
应大幅提高对I-131治疗THCA的关注度。有必要在作者、国家和机构之间构建积极的合作关系，以推动该领域的发展。近期研究涉及THCA中I-131治疗的时机和剂量评估。未来可能聚焦于靶向治疗和不良反应评估的研究也值得关注。
